BioNTech | Sustainability Performance
BioNTech SE is engaged in biotechnology research and development, primarily focused on developing innovative therapies and vaccines for various diseases and conditions.
2008
Germany
5,001 - 10,000 employees
Biotechnology
$1B - 10B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#4429
Overallⓘ#246
in Germanyⓘ#82
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissionsEnergy consumptionGovernance
Targets
Aligned
Controversy level
- BioNTech has faced multiple US patent infringement disputes over its Comirnaty mRNA COVID-19 vaccine including the 2024 USD 791 million Moderna patent ruling, plus the contested 2023 mass layoffs and sustained pharmaceutical pricing scrutiny over US/EU commercial-rate pricing transitions.
